Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma.

Abstract excerpt

INTRODUCTION: Patients with distant metastatic melanoma has a poor prognosis, with a reported median survival time of six to eight months. In modern era, survival has prolonged with the immunotherapy and targeted therapy options. Potent and selective BRAF inhibitors have been developed that specifically inhibit mutated BRAF over other RAF kinases. Vemurafenib was the first selective tyrosine kinase inhibitor...

Topics

Join the communities discussing this publication.

• Disease Progression
• Melanoma
• Mutation
• Progression-Free Survival
• Protein Kinase Inhibitors